The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni®

1Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The advent of direct-acting antiviral agents (DAAs) has revolutionized the treatment and cure of chronic hepatitis C virus (HCV) infection. Herein is described the discovery of ledipasvir (LDV), an orally available HCV nonstructural protein 5A inhibitor with picomolar antiviral potency and a long pharmacokinetic half-life. The combination of LDV with the nonstructural protein 5B inhibitor sofosbuvir (SOF) is Harvoni® and represents the first approved single-tablet regimen for the treatment of HCV infection. This safe simple and efficacious regimen affords clinical trial cure rates over 95% and comparable effectiveness in real-world studies and has treatment durations as short as 8 weeks. The approval of Harvoni® heralded a new era for the treatment of HCV infection.

Cite

CITATION STYLE

APA

Link, J. O. (2019). The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni®. In Topics in Medicinal Chemistry (Vol. 32, pp. 57–80). Springer. https://doi.org/10.1007/7355_2019_66

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free